News Category
Creative Biolabs is spotlighting three-dimensional tumor organoid and immune cell co-culture services that let preclinical researchers study CAR-T act...
Creative Biolabs' new dual-vesicle platform combines OMV and exosome engineering to help researchers overcome CAR-T infiltration, persistence, and saf...
TransCode Therapeutics' TTX-MC138 met its primary safety endpoint in a Phase 1a trial, with no dose-limiting toxicities and early signs of disease sta...
Oncotelic Therapeutics has published a peer-reviewed study showing its PDAOAI platform identified a four-gene prognostic signature in hepatocellular c...
A UK study reveals that clearing immune fog can intercept lung cancer before diagnosis, potentially revolutionizing early treatment and saving lives.
VERAXA Biotech (NASDAQ: VRXA) is implementing FDA-aligned New Approach Methodologies to cut animal testing by up to 95% while accelerating preclinical...
Lantern Pharma's regulatory and IRB approvals in Taiwan for Part 2 of its Phase 2 HARMONIC trial of LP-300 represent a key step in advancing a biomark...
VERAXA Biotech's FDA-aligned New Approach Methodologies could significantly reduce animal testing and accelerate preclinical development of its antibo...
Telomir Pharmaceuticals' $5.6 million PIPE financing will fund the clinical development of Telomir-Zn, a potential first-in-class therapy for triple-n...
New research reveals that the skull may harbor a local immune system for the brain, potentially opening doors to novel treatments for brain diseases a...
Kairos Pharma's ENV-105 combined with apalutamide demonstrated a statistically significant improvement in progression-free survival for metastatic cas...
GeoVax will present its next-generation MVA-X vaccine and continuous cell-line manufacturing platform at a major vaccine conference, potentially trans...
The Hong Kong Convention and Exhibition Centre hosted 786 events and 25 new exhibitions and conferences in FY 2025–2026, reinforcing Hong Kong's role ...
A new intraoperative test developed by the University of Nottingham and deployed by NHS England can identify a brain tumor's genetic makeup in about t...
A new blood-based method for identifying cancer-specific proteins could eliminate the need for surgical tumor biopsies, potentially accelerating the d...
Novogenia AG's H1 2026 report shows revenue decline but core DNA analysis growth, cost reductions, and strategic progress positioning the company for ...
A new protein discovery by South Korean researchers could lead to more effective treatments for glioblastoma, the deadliest form of brain cancer, whil...
GeoVax's next-generation MVA-X vaccine provides durable single-dose protection against highly pathogenic Clade I mpox virus in preclinical models, pot...
Onco-Innovations is aligning manufacturing, preclinical, and regulatory activities for its lead cancer candidate ONC010, aiming to disrupt DNA repair ...
Experts emphasize that asking about clinical trials at the first appointment can open doors to promising new treatments and improved quality of life f...
Telomir Pharmaceuticals' Telomir-Zn demonstrated growth inhibition in human and canine osteosarcoma models, potentially opening a new translational pa...
Dr. Wael Sakr has announced a one-time $1,000 scholarship for undergraduate pre-med students, aiming to reduce financial barriers and encourage divers...
Creative Biolabs has broadened its single-cell and single-nucleus RNA sequencing and multi-omics services to help researchers overcome sample processi...
A comprehensive review reveals that the tumor microenvironment actively sculpts natural killer cells into distinct functional subsets, offering new ta...
The September 17 online forum gives investors direct access to management teams from seven life sciences companies, highlighting advances in photother...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer strengthens its scientific leadership as it advances its BiTAC® platfo...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, has received FDA clearance to begin a Phase 2 trial in multiple sclerosis, marking a si...
Onco-Innovations' CMO discussed the company's lead drug candidate ONC010, which targets the DNA repair enzyme PNKP and has shown promising preclinical...
Quantum BioPharma's FDA clearance for its Lucid-MS IND allows a phase 2 trial in multiple sclerosis, potentially offering a first-in-class treatment t...
Kairos Pharma's CEO presentation at a major investment conference underscores the clinical progress of its lead candidate ENV-105, which aims to rever...
GeoVax supports the new Gavi-funded global mpox vaccine stockpile, emphasizing the need for diversified supply and highlighting its GEO-MVA candidate'...
VERAXA Biotech's appointment of seasoned financial leader Raju Willener as CFO signals a strategic move to strengthen its capital position and advance...
Onco-Innovations has made significant progress in manufacturing, IND-enabling activities, and financing to advance its lead oncology candidate ONC010 ...
OS Animal Health's participation in the Moody Capital conference underscores its strategic push to secure USDA approval for OST-HER2, a promising immu...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS, a first-in-class drug targeting myelin repair, marks a significant step toward addr...
Researchers at Washington University School of Medicine have advanced laser interstitial thermal therapy (LITT) as a less invasive brain cancer treatm...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in a Phase 2 trial marks a pivotal step toward a treatment t...
NanoViricides has registered its Phase II Ebola trial in the DRC, marking a significant step in developing an oral antiviral treatment against Ebola v...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS, a first-in-class drug targeting demyelination in multiple sclerosis, marks a s...
Youth tobacco use in the U.S. has reached historic lows, yet adult smoking remains a leading preventable cause of death, prompting a call for balanced...
A study of 5,617 colorectal cancer patients reveals that the timing of brain metastasis development significantly impacts survival, offering crucial p...
Onco-Innovations' lead candidate ONC010 reaches key preclinical milestones, including 99.3% purity and a novel non-tin catalyst, positioning it for a ...
VERAXA Biotech's appointment of seasoned financial executive Raju Willener as CFO signals a strategic move to strengthen its capital strategy and supp...
OS Therapies' participation in the Moody Capital conference comes as it anticipates critical regulatory decisions and data readouts for its lead candi...
A Swiss preclinical study indicates that administering immunotherapy prior to surgical removal of glioblastoma tumors significantly improves treatment...
New research from Mass General Brigham suggests that minimizing radiation to the thymus during lung cancer treatment could improve patient outcomes, h...
Dr. Salman Fazal, a hematologist and stem cell transplant expert at UPMC Hillman Cancer Center, has been recognized as a Castle Connolly Top Doctor fo...
NanoViricides is progressing its measles drug candidate NV-387 to Phase II trials, leveraging FDA designations and preclinical efficacy to address the...
